Healthcare Industry News: HSMN NewsFeed
News Release - March 26, 2012
BSD Medical Appoints Sam Maravich as Vice President of Sales and MarketingSALT LAKE CITY--(Healthcare Sales & Marketing Network)--BSD Medical Corporation (NASDAQ:BSDM ) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced the addition of Sam Maravich Jr. as Vice President, Sales and Marketing. Sam has a 36-year history in marketing medical equipment to physicians, with a focus on sales of capital equipment in the healthcare market. He was most recently the Director of Sales/Core Devices for Kimberly-Clark Corporation. Sam has an impressive track record in significantly increasing sales, building effective sales teams and establishing successful, long-term customer relationships. Sam will initially focus his efforts exclusively on the worldwide sale of BSD’s MicroThermX® line of products and the implementation of BSD’s new fee-per-use equipment rental program.
“Sam Maravich is a proven performer in the medical device industry. He brings industry experience, an extensive professional network and strong customer focus to the team at BSD. We expect the addition of Sam as Vice President of Sales and Marketing to significantly increase BSD’s market penetration,” said Harold Wolcott, BSD President and CEO. “Sam will be a strong contributor to the successful implementation of our MicroThermX® sales and fee-per-use equipment rental programs throughout the U.S. We are honored to have Sam as a member of our senior management.”
About the MicroThermX® Microwave Ablation System
The MicroThermX® is a compact, mobile, state-of-the-art proprietary system that includes a microwave generator, single-patient-use disposable antennas and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX® is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX® utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure. The MicroThermX® introduces into the Company’s product line innovative, high-end disposables (SynchroWave antennas) that are used in each ablation treatment and will provide a significant ongoing revenue stream. The soft tissue ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX® for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX® System, which allows BSD to market the MicroThermX® in Europe. CE marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX® to a number of international markets.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia), while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market, and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.
Source: BSD Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.